Controversies in the management of stage I seminoma: adjuvant carboplatin revisited
- 4 Downloads
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
For this type of study formal consent is not required.
- 1.Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, Nicolai N, Nichols C. Non-risk-adapted surveillance for stage I testicular cancer: critical review and summary. Eur Urol 2018. https://doi.org/10.1016/j.eururo.2017.12.030. (Epub ahead of print).
- 8.Tandstad T, Stahl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27:1299–304.CrossRefPubMedGoogle Scholar
© Federación de Sociedades Españolas de Oncología (FESEO) 2018